You will be shown inclusion or exclusion criteria for a clinical trial. Given these criteria, your task is to extract all unique entities of the following types: ["Observation", "Condition", "Procedure", "Drug", "Temporal", "Multiplier", "Qualifier", "Negation", "ReferencePoint", "Scope", "Value", "Mood", "Device", "Visit", "Measurement", "Person"].

Please return the output as a JSON object of the format: {"Condition" : ["breast cancer", ...], "Device" : ["ports", ...], "Drug" : ["Atenolol", ...], "Measurement" : ["blood pressure", ...], "Mood" : ["suspected", ...], "Multiplier" : ["more than two", ...], "Negation" : ["no", ...], "Observation" : ["history", ...], "Person" : ["male", ...], "Procedure" : ["surgery", ...], "Qualifier" : ["severe", ...], "ReferencePoint" : ["enrollment", ...], "Scope" : ["infection", ...], "Temporal" : ["one day", ...], "Value" : ["50%", ...], "Visit" : ["ICU", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

History or known presence of central nervous system metastases.
History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to panitumumab or excipients that contraindicates their participation.
Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (e.g., panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib).
Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy <=30 days before first dose of study treatment or not recovered from any acute toxicity.
Other investigational procedure <=30 days before study entry.
History of interstitial lung disease (ILD) e.g., interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography.
Subject previously enrolled to this study.
History of keratitis, ulcerative keratitis or severe dry eye.
Major surgery (e.g., requiring general anesthesia) <=30 days before first dose of study treatment. Subjects must have recovered from any surgery related toxicities.
Minor surgical procedure (e.g., open biopsy) <=7 days before first dose of study treatment, or not yet recovered from prior minor surgery Note: uncomplicated placement of vascular access device, fine needle aspiration, thoracocentesis or paracentesis >=3 days prior to first dose of study treatment is acceptable.
Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) <=6 months prior to enrolment.
History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with the study participation or investigational product administration, compliance with the study procedures or may interfere with the interpretation of the results.
Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event <=30 days before first dose of study treatment. If on anticoagulation, subject must be on stable therapeutic dose prior to first dose of study treatment.
Subject who is pregnant or breast feeding, or planning to become pregnant during treatment and within 2 months after the discontinuation of study treatment.
Known positive test(s) for human immunodeficiency virus infection (testing is not required in the absence of clinical suspicion).
Active infection requiring systemic treatment or any uncontrolled infection <=14 days prior to first dose of study treatment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).
Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures or is unwilling or unable to comply with study requirements.
{"Condition": ["cardiac arrhythmia", "mediate o persensitivity reaction o", "Malignancy", "urinary tract infection", "idiosyncrasy", "delayed hypersensitivity reaction", "upper respiratory tract infection", "congestive heart failure", "not recovered from any acute toxicity", "infection", "active disease", "us throm c event \u003c=30 days be", "interstitial lung disease", "deep vein thrombosis", "dry eye", "malignancy", "unstable angina", "Prostatic intraepithelial neoplasia", "cardiovascular disease", "myocardial infarction", "pulmonary embolism", "uncontrolled infection", "non-melanomatous skin cancer", "evidence of disease", "pregnant", "venous thromboembolic event", "recurrence", "cervical carcinoma in situ", "disease", "ILD", "keratitis", "prostate cancer", "recovered", "lentigo maligna", "central nervous system metastases", "ulcerative keratitis", "pulmonary fibrosis", "interstitial pneumonitis"], "Device": [], "Drug": ["cetuximab", "gefitinib", "ugs chemically related to panitumumab o cipients t", "lapatinib", "drugs chemically related to panitumumab", "erlotinib", "panitumumab", "investigational agent"], "Measurement": ["test(s) for human immunodeficiency virus infection"], "Mood": ["evidence of", "planning to", "felt to be at low risk"], "Multiplier": ["therapeutic dose"], "Negation": ["except", "no", "not yet", "with the exception of", "without"], "Observation": ["breast feeding", "become pregnant"], "Person": [], "Procedure": ["minor surgery", "treated with curative intent", "radiotherapy", "Major surgery", "systemic treatment", "antibody therapy", "hormonal therapy", "chest computer tomography", "treatment with small molecule EGFr inhibitors", "treated", "EGFr", "open biopsy", "anticoagulation", "Minor surgical procedure", "investigational procedure", "chemotherapy", "i-epidermal growth factor receptor (E ibody therapy (e", "immunotherapy", "therapy", "Antitumor therapy", "general anesthesia"], "Qualifier": ["symptomatic", "another", "Unstable", "Clinically significant", "significant", "Adequately", "severe", "serious", "Other", "other", "uncomplicated", "any", "stable", "uncontrolled"], "ReferencePoint": ["treatment", "the discontinuation of study treatment", "first dose of study treatment", "enrolment"], "Scope": ["interstitial lung disease (ILD)", "pregnant or breast feeding, or planning to become pregnant", "Active infection requiring systemic treatment or any uncontrolled infection", "drugs chemically related to panitumumab or excipients", "Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy", "gefitinib, erlotinib, lapatinib", "panitumumab or cetuximab", "Malignancy treated with curative intent and with no known active disease present for \u003e=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer", "during treatment and within 2 months after the discontinuation of study treatment", "uncomplicated urinary tract infection or upper respiratory tract infection", "Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event", "non-melanomatous skin cancer or lentigo maligna", "arterial/venous thromboembolic event", "myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia", "interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography", "chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy", "Clinically significant cardiovascular disease"], "Temporal": ["\u003c=7 days before first dose of study treatment", "for \u003e=5 years prior to enrolment", "\u003c=30 days before study entry", "\u003c=30 days before first dose of study treatment", "during treatment", "prior", "baseline", "Active", "prior to first dose of study treatment", "\u003c=6 months prior to enrolment", "within 2 months after the discontinuation of study treatment", "\u003c=14 days prior to first dose of study treatment"], "Value": ["positive"], "Visit": []}